A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

NCT04302103 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Myasthenia Gravis

Interventions

BIOLOGICAL: RC18 160mg
BIOLOGICAL: RC18 240 mg

Sponsor

RemeGen Co., Ltd.